How much dystrophin is enough: The physiological consequences of different levels of dystrophin in the mdx mouse

Human Molecular Genetics

Volumn 24, Issue 15, 2015, Pages 4225-4237

  Godfrey, Caroline ^a   Muses, Sofia ^b   McClorey, Graham ^a   Wells, Kim E ^b   Coursindel, Thibault ^c,d   Terry, Rebecca L ^b   Betts, Corinne ^a   Hammond, Suzan ^a   O’Donovan, Liz ^c   Hildyard, John ^b   Andaloussi, Samir El ^a,e   Gait, Michael J ^c   Wood, Matthew J ^a   Wells, Dominic J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^d Les Coteaux Saint Roch   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; CELL PENETRATING PEPTIDE; DYSTROPHIN; GELATINASE B; INTRALIPID; LAMININ; LIPID EMULSION; MICRORNA; MORPHOLINO OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; PEPTIDE; PIP6A PEPTIDE; PIP6A PMO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VINCULIN; ANTISENSE OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE; CARDIAC PUNCTURE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DENSITOMETRY; DISEASE EXACERBATION; DUCHENNE MUSCULAR DYSTROPHY; ECCENTRIC MUSCLE CONTRACTION; EXON SKIPPING; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOGRAM; HISTOLOGY; IMMUNOHISTOCHEMISTRY; ION EXCHANGE CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; MULTIPLEX REAL TIME POLYMERASE CHAIN REACTION; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE STRENGTH; NONHUMAN; PHAGE DISPLAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SARCOLEMMA; TIBIALIS ANTERIOR MUSCLE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; METABOLISM; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CELL-PENETRATING PEPTIDES; DISEASE MODELS, ANIMAL; DYSTROPHIN; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE;

EID: 85018214528     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv155     Document Type: Article

References (49)

1. Manzur, A.Y., Kinali, M. and Muntoni, F. (2008) Update on the management of Duchenne muscular dystrophy. Arch. Dis. Child., 93, 986–990.
2. Muntoni, F. and Wood, M.J. (2011) Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov., 10, 621–637.
3. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595–605.
4. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platen-burg, G.J., Sipkens, J.A. et al. (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N. Engl. J. Med., 364, 1513–1522.
5. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol., 8, 918–928.
6. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl.J. Med., 357, 2677–2686.
7. Lu, Q.L., Cirak, S. and Partridge, T. (2014) What Can We Learn From Clinical Trials of Exon Skipping for DMD? Mol. Ther. Nucleic Acids., 3, e152.
8. Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P., Rimessi, P., Gualandi, F., Sewry, C. et al. (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord., 17, 913–918.
9. Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomeza, V., Armaroli, A., Guglieri, M., Straathof, C.S., Verschuuren, J.J. et al. (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain, 134, 3547–3559.
10. Phelps, S.F., Hauser, M.A., Cole, N.M., Rafael, J.A., Hinkle, R.T., Faulkner, J.A. and Chamberlain, J.S. (1995) Expression of full length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet., 4, 1251–1258.
11. Wells, D.J., Wells, K.E., Asante, E.A., Turner, G., Sunada, Y., Campbell, K.P., Walsh, F.S. and Dickson, G. (1995) Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum. Mol. Genet., 4, 1245–1250.
12. Li, D., Yue, Y. and Duan, D. (2008) Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am. J. Pathol., 172, 1332–1341.
13. Li, D., Yue, Y. and Duan, D. (2010) Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. PLoS One, 5, e15286.
14. van Putten, M., Hulsker, M., Nadarajah, V.D., van Heiningen, S.H., van Huizen, E., van Iterson, M., Admiraal, P., Messemaker, T., den Dunnen, J.T., t Hoen, P.A.C. et al. (2012) The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One, 7, e31937.
15. Bulfield, G., Siller, W.G., Wight, P.A. and Moore, K.J. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. U S A., 81, 1189–1192.
16. Coulton, G.R., Morgan, J.E., Partridge, T.A. and Sloper, J.C. (1988) The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol. Appl. Neurobiol., 14, 53–70.
17. Dangain, J. and Vrbova, G. (1984) Muscle development in mdx mutant mice. Muscle Nerve, 7, 700–704.
18. Tanabe, Y., Esaki, K. and Nomura, T. (1986) Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta. Neuropathol., 69, 91–95.
19. Betts, C., Saleh, A.F., Arzumanov, A.A., Hammond, S.M., Godfrey, C., Coursindel, T., Gait, M.J. and Wood, M.J. (2012) Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol. Ther. Nucleic Acids., 1, e38.
20. Foster, H., Sharp, P.S., Athanasopoulos, T., Trollet, C., Graham, I.R., Foster, K., Wells, D.J. and Dickson, G. (2008) Codon and mRNA sequence optimization of microdystrophin trans-genes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther., 16, 1825–1832.
21. Miller, G., Moore, C.J., Terry, R., La Riviere, T., Mitchell, A., Piggott, R., Dear, T.N., Wells, D.J. and Winder, S.J. (2012) Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse. Hum. Mol. Genet., 21, 4508–4520.
22. Terry, R.L., Kaneb, H.M. and Wells, D.J. (2014) Poloxomer 188 has a deleterious effect on dystrophic skeletal muscle function. PLoS One, 9, e91221.
23. Whitmore, C., Fernandez-Fuente, M., Booler, H., Parr, C., Kavishwar, M., Ashraf, A., Lacey, E., Kim, J., Terry, R., Ackroyd, M.R. et al. (2014) The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Hum. Mol. Genet., 23, 1842–1855.
24. Crisp, A., Yin, H., Goyenvalle, A., Betts, C., Moulton, H.M., Seow, Y., Babbs, A., Merritt, T., Saleh, A.F., Gait, M.J. et al. (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum. Mol. Genet., 20, 413–421.
25. Yin, H., Moulton, H.M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P. and Wood, M.J. (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet., 17, 3909–3918.
26. Yin, H., Moulton, H.M., Betts, C., Seow, Y., Boutilier, J., Iverson, P.L. and Wood, M.J. (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet., 18, 4405–4414.
27. Yin, H., Moulton, H.M., Betts, C., Merritt, T., Seow, Y., Ashraf, S., Wang, Q., Boutilier, J. and Wood, M.J. (2010) Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol. Ther., 18, 1822–1829.
28. Jearawiriyapaisarn, N., Moulton, H.M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P.L. and Kole, R. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther., 16, 1624–1629.
29. Samoylova, T.I. and Smith, B.F. (1999) Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve, 22, 460–466.
30. Perez, F., Joliot, A., Bloch-Gallego, E., Zahraoui, A., Triller, A. and Prochiantz, A. (1992) Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J. Cell. Sci., 102, 717–722.
31. Boisguerin, P., Deshayes, S., Gait, M.J., O’Donovan, L., Godfrey, C., Betts, C.A., Wood, M.J. and Lebleu, B. (2015) Delivery of therapeutic oligonucleotides with cell penetrating peptides. Adv. Drug. Deliv. Rev., 4, 00019–00018.
32. van Putten, M., Hulsker, M., Young, C., Nadarajah, V.D., Heemskerk, H., van der Weerd, L., t Hoen, P.A., van Ommen, G.J. and Aartsma-Rus, A.M. (2013) Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J., 27, 2484–2495.
33. Heemskerk, H., de Winter, C., van Kuik, P., Heuvelmans, N., Sabatelli, P., Rimessi, P., Braghetta, P., van Ommen, G.J., de Kimpe, S., Ferlini, A. et al. (2010) Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther., 18, 1210–1217.
34. Chan, S., Head, S.I. and Morley, J.W. (2007) Branched fibers in dystrophic mdx muscle are associated with a loss of force following lengthening contractions. Am. J. Physiol. Cell. Physiol., 293, 985–992.
35. Dellorusso, C., Crawford, R.W., Chamberlain, J.S. and Brooks, S.V. (2001) Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle. Res. Cell. Motil., 22, 467–475.
36. DelloRusso, C., Scott, J.M., Hartigan-O’Connor, D., Salvatori, G., Barjot, C., Robinson, A.S., Crawford, R.W., Brooks, S.V. and Chamberlain, J.S. (2002) Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl Acad. Sci. USA, 99, 12979–12984.
37. Sharp, P.S., Bye-a-Jee, H. and Wells, D.J. (2011) Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol. Ther., 19, 165–171.
38. Cacchiarelli, D., Incitti, T., Martone, J., Cesana, M., Cazzella, V., Santini, T., Sthandier, O. and Bozzoni, I. (2011) miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep., 12, 136–141.
39. Aoki, Y., Nakamura, A., Yokota, T., Saito, T., Okazawa, H., Nagata, T. and Takeda, S. (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol. Ther., 18, 1995–2005.
40. Malerba, A., Sharp, P.S., Graham, I.R., Arechavala-Gomeza, V., Foster, K., Muntoni, F., Wells, D.J. and Dickson, G. (2011) Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol. Ther., 19, 345–354.
41. Heier, C.R., Damsker, J.M., Yu, Q., Dillingham, B.C., Huynh, T., Van der Meulen, J.H., Sali, A., Miller, B.K., Phadke, A., Scheffer, L. et al. (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med., 5, 1569–1585.
42. Wu, B., Cloer, C., Lu, P., Milazi, S., Shaban, M., Shah, S.N., Marston-Poe, L., Moulton, H.M. and Lu, Q.L. (2014) Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice. Gene Ther., 21, 785–793.
43. Stedman, H.H., Sweeney, H.L., Shrager, J.B., Maguire, H.C., Panettieri, R.A., Petrof, B., Narusawa, M., Leferovich, J.M., Sladky, J.T. and Kelly, A.M. (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature, 352, 536–539.
44. Roberts, T.C., Blomberg, K.E., McClorey, G., El Andaloussi, S., Godfrey, C., Betts, C., Coursindel, T., Gait, M.J., Smith, C.I. and Wood, M.J. (2012) Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol. Ther. Nucleic Acids, 1, e39.
45. Zaharieva, I.T., Calissano, M., Scoto, M., Preston, M., Cirak, S., Feng, L., Collins, J., Kole, R., Guglieri, M., Straub, V. et al. (2013) Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS One, 8, e80263.
46. Nadarajah, V.D., van Putten, M., Chaouch, A., Garrood, P., Straub, V., Lochmuller, H., Ginjaar, H.B., Aartsma-Rus, A.M., van Ommen, G.J., den Dunnen, J.T. et al. (2011) Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord., 21, 569–578.
47. Arechavala-Gomeza, V., Kinali, M., Feng, L., Brown, S.C., Sewry, C., Morgan, J.E. and Muntoni, F. (2010) Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol. Appl. Neurobiol., 36, 265–274.
48. Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T. and Magyar, J.P. (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord., 14, 675–682.
49. Wells, D.J., Wells, K.E., Walsh, F.S., Davies, K.E., Goldspink, G., Love, D.R., Chan-Thomas, P., Dunckley, M.G., Piper, T. and Dickson, G. (1992) Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. Hum. Mol. Genet., 1, 35–40.